Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.

CONTEXT Studies have found that patients with acute coronary syndromes (ACS) often do not receive evidence-based therapies in community practice. This is particularly true in low- and middle-income countries. OBJECTIVE To evaluate whether a multifaceted quality improvement (QI) intervention can improve the use of evidence-based therapies and reduce the incidence of major cardiovascular events among patients with ACS in a middle-income country. DESIGN, SETTING, AND PARTICIPANTS The BRIDGE-ACS (Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes) trial, a cluster-randomized (concealed allocation) trial conducted among 34 clusters (public hospitals) in Brazil and enrolling a total of 1150 patients with ACS from March 15, 2011, through November 2, 2011, with follow-up through January 27, 2012. INTERVENTION Multifaceted QI intervention including educational materials for clinicians, reminders, algorithms, and case manager training, vs routine practice (control). MAIN OUTCOME MEASURES Primary end point was the percentage of eligible patients who received all evidence-based therapies (aspirin, clopidogrel, anticoagulants, and statins) during the first 24 hours in patients without contraindications. RESULTS Mean age of the patients enrolled was 62 (SD, 13) years; 68.6% were men, and 40% presented with ST-segment elevation myocardial infarction, 35.6% with non-ST-segment elevation myocardial infarction, and 23.6% with unstable angina. The randomized clusters included 79.5% teaching hospitals, all from major urban areas and 41.2% with 24-hour percutaneous coronary intervention capabilities. Among eligible patients (923/1150 [80.3%]), 67.9% in the intervention vs 49.5% in the control group received all eligible acute therapies (population average odds ratio [OR(PA)], 2.64 [95% CI, 1.28-5.45]). Similarly, among eligible patients (801/1150 [69.7%]), those in the intervention group were more likely to receive all eligible acute and discharge medications (50.9% vs 31.9%; OR(PA),, 2.49 [95% CI, 1.08-5.74]). Overall composite adherence scores were higher in the intervention clusters (89% vs 81.4%; mean difference, 8.6% [95% CI, 2.2%-15.0%]). In-hospital cardiovascular event rates were 5.5% in the intervention group vs 7.0% in the control group (OR(PA), 0.72 [95% CI, 0.36-1.43]); 30-day all-cause mortality was 7.0% vs 8.4% (ORPA, 0.79 [95% CI, 0.46-1.34]). CONCLUSION Among patients with ACS treated in Brazil, a multifaceted educational intervention resulted in significant improvement in the use of evidence-based therapies. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00958958.

[1]  B. Giraudeau,et al.  [Cluster randomised trials]. , 2014, Annales de dermatologie et de venereologie.

[2]  E. Peterson,et al.  A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: rationale and design of the Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes (BRIDGE-ACS) cluster-randomized trial. , 2012, American heart journal.

[3]  N. Wenger 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST‐Elevation Myocardial Infarction (Updating the 2007 Guideline): Highlights for the Clinician , 2012, Clinical cardiology.

[4]  Hani Jneid,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[5]  Sean M. O'Brien,et al.  Comparison of Composite Measure Methodologies for Rewarding Quality of Care: An Analysis From the American Heart Association's Get With The Guidelines Program , 2011, Circulation. Cardiovascular quality and outcomes.

[6]  M. Flather,et al.  Cluster-randomized trial to evaluate the effects of a quality improvement program on management of non-ST-elevation acute coronary syndromes: The European Quality Improvement Programme for Acute Coronary Syndromes (EQUIP-ACS). , 2011, American Heart Journal.

[7]  S. Yusuf,et al.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.

[8]  L. A. Mattos Racionalidade e métodos do registro ACCEPT - Registro Brasileiro da Prática Clínica nas Síndromes Coronarianas Agudas da Sociedade Brasileira de Cardiologia , 2011 .

[9]  Bruce Bartholow Duncan,et al.  Chronic non-communicable diseases in Brazil: burden and current challenges , 2011, The Lancet.

[10]  L. Mattos Rationality and methods of ACCEPT registry - Brazilian registry of clinical practice in acute coronary syndromes of the Brazilian Society of Cardiology. , 2011, Arquivos brasileiros de cardiologia.

[11]  C. Cannon,et al.  Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies , 2011, Circulation.

[12]  M. Flather,et al.  Improving the management of non-ST elevation acute coronary syndromes: systematic evaluation of a quality improvement programme European QUality Improvement Programme for Acute Coronary Syndrome: The EQUIP-ACS project protocol and design , 2010, Trials.

[13]  J. Ornato,et al.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  Frauke Kreuter,et al.  A Survey on Survey Statistics: What is Done and Can be Done in Stata , 2007 .

[15]  A Donner,et al.  Developments in cluster randomized trials and Statistics in Medicine , 2007, Statistics in medicine.

[16]  L. Newby,et al.  A comparison of acute coronary syndrome care at academic and nonacademic hospitals. , 2007, The American journal of medicine.

[17]  L. Wallentin,et al.  Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. , 2006, American heart journal.

[18]  Elizabeth R DeLong,et al.  Association between hospital process performance and outcomes among patients with acute coronary syndromes. , 2006, JAMA.

[19]  Luke Vale,et al.  Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966-1998. , 2006, Journal of general internal medicine.

[20]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[21]  Colin Mathers,et al.  Preventing chronic diseases: how many lives can we save? , 2005, The Lancet.

[22]  Jack V Tu,et al.  Administrative Data Feedback for Effective Cardiac Treatment: AFFECT, a cluster randomized trial. , 2005, JAMA.

[23]  J. Grimshaw,et al.  Cluster Randomized Trials of Professional and Organizational Behavior Change Interventions in Health Care Settings , 2005 .

[24]  Nick Steen,et al.  Guiding the design and selection of interventions to influence the implementation of evidence-based practice: an experimental simulation of a complex intervention trial. , 2005, Social science & medicine.

[25]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[26]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[27]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[28]  Á. Avezum,et al.  Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). , 2003, American heart journal.

[29]  C. Polanczyk,et al.  Improvement in clinical outcomes in acute coronary syndromes after the implementation of a critical pathway. , 2003, Critical pathways in cardiology.

[30]  D. Torgerson,et al.  Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals , 2003, BMJ : British Medical Journal.

[31]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[32]  Robert H Christenson,et al.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[33]  W Klein,et al.  Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). , 2002, European heart journal.

[34]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[35]  S. Yusuf,et al.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.

[36]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[37]  Jeremy M. Grimshaw,et al.  Changing Provider Behavior: An Overview of Systematic Reviews of Interventions , 2001, Medical care.

[38]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[39]  R. Centor,et al.  Relationship of hospital teaching status with quality of care and mortality for Medicare patients with acute MI. , 2000, JAMA.

[40]  M Eccles,et al.  Experimental and quasi-experimental designs for evaluating guideline implementation strategies. , 2000, Family practice.

[41]  P. Lachenbruch,et al.  The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. , 1999, Statistics in medicine.

[42]  M. Cabana,et al.  Why don't physicians follow clinical practice guidelines? A framework for improvement. , 1999, JAMA.

[43]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[44]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[45]  Alan D. Lopez,et al.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study , 1997, The Lancet.

[46]  B J McNeil,et al.  Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. , 1994, The New England journal of medicine.

[47]  Fibrinolytictherapytrialistsf Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[48]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .